Antioxidant Therapy for Management of Oxidative Stress Induced Hypertension

Dear Colleagues,

Hypertension, defined as elevated blood pressure, if the systolic blood pressure is more than 140 mmHg, and or the diastolic blood pressure is higher than 90 mmHg, measured on two different days. Hypertension represents a medical condition that increases significantly risk for cardiovascular, cerebrovascular, and chronic kidney diseases. Besides, it is considered a leading cause of mortality and morbidity worldwide.

The mechanisms underlying the pathological processes of hypertension are not completely clarified. However, relevant evidence correlates the increase of oxidative stress with the development of hypertension. Results of preclinical and clinical studies have demonstrated the crucial role of oxidants compounds and oxidative phenomena in the progression of hypertension. In particular, oxidative stress due to hypertension is associated with endothelial dysfunction in the vessels. Based on World Health Organization guidelines, adults with hypertension requiring treatment from any of three classes of antihypertensive drugs such as thiazide, and thiazide-like agents, angiotensin-converting enzyme inhibitors, or angiotensin-receptor blockers, and long-acting dihydropyridine calcium channel blockers. Since reactive oxygen species are a primary trigger of hypertension, antioxidant therapy would have a favorable effect on hypertension's consequences. In particular, the reduction of oxidative stress could represent a strategy to prevent cardiovascular events in hypertensive patients.

The main goal of this special issue is to highlight different aspects of the involvement of oxidative stress in the development of hypertension, and correlated end-organ damage processes. The special issue will be focused on the mechanisms that would explain this correlation. This issue, therefore, can include publishing preclinical and clinical reports or reviews relating to any of the following topics: hypertension, reactive oxygen species production, oxidative stress, endothelial dysfunction, neurodegeneration, antihypertensive drugs, and their role as antioxidants, antioxidant treatment, or antioxidant supplementation.

We look forward to your contribution.

Dr. Daniele Tomassoni
Dr. Seyed Khosrow Tayebati
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antioxidants is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• hypertension
• oxidative stress
• antioxidant
• cardiovascular and cerebrovascular disease
• therapy